AstraZeneca Announces Completion Of Exclusive License Agreement With Dizal Pharmaceutical For Worldwide Rights To ZEGFROVY For $600M Upfront, Up To $900M In Milestones, Plus Tiered Royalties; US Launch Planned Q4 2026

Loading news article.

AstraZeneca Announces Completion Of Exclusive License Agreement With Dizal Pharmaceutical For Worldwide Rights To ZEGFROVY For $600M Upfront, Up To $900M In Milestones, Plus Tiered Royalties; US Launch Planned Q4 2026 | WAPE

AstraZeneca Announces Completion Of Exclusive License Agreement With Dizal Pharmaceutical For Worldwide Rights To ZEGFROVY For $600M Upfront, Up To $900M In Milestones, Plus Tiered Royalties; US Launch Planned Q4 2026

Article summary

Related companies

Comments —